Hepatocellular nodules in liver cirrhosis: Contrast-enhanced MR

Abdominal Imaging

Volumn 36, Issue 3, 2011, Pages 290-299

  Bartolozzi, Carlo ^a   Battaglia, Valentina ^a   Bozzi, Elena ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cirrhosis; HCC; Liver; MR; MR hepatospecific contrast agents

Indexed keywords

CONTRAST MEDIUM; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOLINIUM CHELATE; GADOXETIC ACID;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DYSPLASIA; HUMAN; KUPFFER CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LIVER REGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING;

EID: 79960300890     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-011-9687-z     Document Type: Article

References (31)

1. C Bartolozzi L Crocetti R Lencioni, et al. 2007 Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media Eur Radiol 17 10 2519 2530 17429640 10.1007/s00330-007-0602-5
2. MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone
3. SS Ahn MJ Kim JS Lim, et al. 2010 Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 225 2 459 466 10.1148/radiol.10091388
4. M Kanematsu, et al. 2008 Magnetic resonance imaging of hepatocellular carcinoma Oncology 75 Suppl 1 65 71 19092274 10.1159/000173426
5. SH Kim SH Kim J Lee, et al. 2009 Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma AJR Am J Roentgenol 192 1675 1681 19457834 10.2214/AJR.08.1262
6. P Reimer G Schneider W Schima, et al. 2004 Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications Eur Radiol 14 559 578 14986050 10.1007/s00330-004-2236-1 (Pubitemid 38444568)
7. MA Kirchin GP Pirovano A Spinazzi, et al. 1998 Gadobenate dimeglumine (Gd-BOPTA). An overview Invest Radiol 33 798 809 9818314 10.1097/00004424- 199811000-00003 1:CAS:528:DyaK1cXnsFGrsbk%3D (Pubitemid 30247065)
8. A Giovagnoni E Paci 1996 Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg) Magn Reson Imaging Clin N Am Feb 4 1 61 72 1:STN:280:DyaK283jtFegsQ%3D%3D (Pubitemid 26091982)
9. A Spinazzi V Lorusso G Pirovano, et al. 1998 Multihance clinical pharmacology: biodistribution and MR enhancement of the liver Acad Radiol 5 Suppl 1 S86 S89 9561052 10.1016/S1076-6332(98)80069-X
10. B Hamm T Stacks A Muhler, et al. 1995 Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging Radiology 195 785 792 7754011 1:STN:280:DyaK2M3ntlGrsg%3D%3D
11. SS Raman C Leary DA Bluemke, et al. 2010 Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial J Comput Assist Tomogr 34 2 163 172 20351497 10.1097/RCT.0b013e3181c89d87
12. T Ichicawa K Saito N Yoshioka, et al. 2010 Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease Invest Radiol 45 3 133 141 10.1097/RLI.0b013e3181caea5b
13. MK Seale OA Catalano S Saini, et al. 2009 Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree Radiographics 29 6 1725 1748 19959518 10.1148/rg.296095515
14. P Reimer T Balzer 2003 Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications Eur Radiol 13 1266 1276 12764641 (Pubitemid 36790627)
15. K Ito 2006 Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging Eur J Radiol 58 186 199 16413154 10.1016/j.ejrad.2005.11.039
16. JY Lee SH Kim YH Jeon, et al. 2010 Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience J Comput Assist Tomogr 34 1 127 134 20118735 10.1097/RCT.0b013e3181b1587a
17. MT Lavelle VS Lee NM Rofsky, et al. 2001 Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy Radiology 218 2 389 394 11161151 1:STN:280:DC%2BD3M3lvVaqtg%3D%3D (Pubitemid 32121048)
18. K Mori H Yoshioka N Takahashi, et al. 2005 Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging AJR Am J Roentgenol 184 1 63 69 15615952 (Pubitemid 40040906)
19. HK Hussain FJ Londy IR Francis, et al. 2003 Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method Radiology 226 558 566 12563155 10.1148/radiol.2262011593 (Pubitemid 36313450)
20. PR Ros PC Freeny SE Harms, et al. 1995 Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions Radiology 196 481 488 7617864 1:STN:280:DyaK2MzktlWitw%3D%3D
21. M Roncalli E Roz G Coggi, et al. 1999 The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification Hepatology 30 5 1174 1178 10534338 10.1002/hep.510300507 1:STN:280:DC%2BD3c%2FgsVKjtA%3D%3D (Pubitemid 29510855)
22. International Consensus Group for Hepatocellular Neoplasia 2009 The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia Hepatology 49 2 658 664 10.1002/hep.22709
23. ND Theise YN Park M Kojiro, et al. 2002 Dysplastic nodules and hepatocarcinogenesis Clin Liver Dis 6 2 497 512 12122867 10.1016/S1089-3261(02) 00006-5 (Pubitemid 34755902)
24. R Shinmura O Matsui S Kobayashi, et al. 2006 Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply Radiology 237 2 512 519 10.1148/radiol.2372041389 (Pubitemid 41507888)
25. J Bruix M Sherman JM Llovet, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 3 421 430 11592607 10.1016/S0168-8278(01)00130-1 1:STN:280:DC%2BD3MrksFCmtg%3D%3D (Pubitemid 32844200)
26. J Bruix M Sherman 2005 Management of hepatocellular carcinoma Hepatology 42 5 1208 1236 16250051 10.1002/hep.20933 (Pubitemid 43112690)
27. JI Kim JM Lee JY Choi, et al. 2008 The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver Invest Radiol 43 3 202 210 18301317 10.1097/RLI.0b013e31815d6929 1:CAS:528:DC%2BD1cXisVWht70%3D (Pubitemid 351643147)
28. JH Lim D Choi SK Cho, et al. 2001 Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number Radiology 220 669 676 11526265 10.1148/radiol.2203001777 1:STN:280:DC%2BD3MvosFemtA%3D%3D (Pubitemid 32799973)
29. RC Chen JM Lii CT Chou, et al. 2008 T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules J Formos Med Assoc 107 10 798 805 18926947 10.1016/S0929-6646(08)60193-X 1:CAS:528:DC%2BD1cXhsVOktL7E
30. V Mazzaferro E Regalia R Doci, et al. 1996 Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 69 693 10.1056/NEJM199603143341104 (Pubitemid 26079803)
31. JM Llovet AM Di Bisceglie J Bruix, et al. 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 698 711 18477802 10.1093/jnci/djn134